Catalog4 refs
Lanreotide
OtherResearch use only
Educational use only. Not medical advice. Verify all information with primary sources and a licensed clinician before use.
Body Map
neuroendocrine tumor cells
Overview
An eight-amino-acid somatostatin analog, a close cousin of octreotide, given as a long-acting deep-injection gel (Somatuline Depot/Autogel) usually once a month. FDA-approved for acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP-NETs), with an approval for carcinoid syndrome. Binds the somatostatin receptor family with strong preference for SSTR2 and SSTR5, suppressing growth hormone release from pituitary cells (lowering IGF-1) and exerting direct antiproliferative, growth-slowing effects on neuroendocrine tumor cells. The supersaturated gel formulation forms a depot under the skin that releases the peptide slowly over about four weeks.
Primary Uses
Acromegaly
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
Carcinoid syndrome
Suppressing growth hormone release
Lowering IGF-1 levels
Slowing neuroendocrine tumor growth
Protocol Reference
Dose
60-120 mg
Frequency
Every 4 weeks
Half-life
~4 weeks (depot formulation releases slowly over approximately four weeks)
Route
Deep subcutaneous injection
Evidence
FDA Approved
Research References· 2
Research Models
Human
Also in Other